A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer
Yang Zhang,
Zi‐Xian Wang,
Lin Shen,
Jin Li,
Jing Huang,
Wei‐Guo Su,
Dong‐Sheng Zhang,
Rui‐Hua Xu
Affiliations
Yang Zhang
Department of Clinical Research, Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China
Zi‐Xian Wang
Department of Medical Oncology Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
Lin Shen
Department of Gastrointestinal Oncology Beijing Cancer Hospital Beijing P. R. China
Jin Li
Department of Medical Oncology Fudan University Shanghai Cancer Center Shanghai Medical College Shanghai P. R. China
Jing Huang
Department of Medical Oncology Cancer Hospital Chinese Academy of Medical Sciences Beijing P. R. China
Wei‐Guo Su
HUTCHMED limited Shanghai P. R. China
Dong‐Sheng Zhang
Department of Medical Oncology Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
Rui‐Hua Xu
Department of Medical Oncology Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China
